PMID- 28457985
OWN - NLM
STAT- MEDLINE
DCOM- 20170619
LR  - 20170619
IS  - 1879-0038 (Electronic)
IS  - 0378-1119 (Linking)
VI  - 624
DP  - 2017 Aug 15
TI  - Validation of aspirin response-related transcripts in patients with coronary 
      artery disease and preliminary investigation on CMTM5 function.
PG  - 56-65
LID - S0378-1119(17)30303-7 [pii]
LID - 10.1016/j.gene.2017.04.041 [doi]
AB  - Aspirin is widely used in the prevention of cardiovascular diseases, but the 
      antiplatelet responses vary from one patient to another. To validate aspirin 
      response related transcripts and illustrate their roles in predicting 
      cardiovascular events, we have quantified the relative expression of 14 
      transcripts previously identified as related to high on-aspirin platelet 
      reactivity (HAPR) in 223 patients with coronary artery disease (CAD) on regular 
      aspirin treatment. All patients were followed up regularly for cardiovascular 
      events (CVE). The mean age of our enrolled population was 75.80+/-8.57years. HAPR 
      patients showed no significant differences in terms of co-morbidities and 
      combined drugs. Besides, the relative expression of HLA-DQA1 was significantly 
      lower in low on-aspirin platelet reactivity (LAPR) patients, when compared with 
      HAPR and high normal (HN) group (p=0.028). What's more, the number of arteries 
      involved, HAPR status and the relative expression of CLU, CMTM5 and SPARC were 
      independent risk factors for CVE during follow up (p<0.05). In addition, 
      overexpression of CMTM5 attenuated endothelial cells (ECs) migration and 
      proliferation, with significantly decreased phosphorylated-Akt levels, while its 
      inhibition promoted these processes in vitro (p<0.05).Our study provides evidence 
      that circulating transcripts might be potential biomarkers in predicting 
      cardiovascular events. CMTM5 might exert anti-atherosclerotic effects via 
      suppressing migration and proliferation in the vessel wall. Nevertheless, 
      larger-scale and long-term studies are still needed.
CI  - Copyright (c) 2017 Elsevier B.V. All rights reserved.
FAU - Zhang, J W
AU  - Zhang JW
AD  - Department of Geriatrics, Peking University First Hospital, Beijing, China.
FAU - Liu, T F
AU  - Liu TF
AD  - Department of Geriatrics, Peking University First Hospital, Beijing, China.
FAU - Chen, X H
AU  - Chen XH
AD  - Department of Geriatrics, Peking University First Hospital, Beijing, China.
FAU - Liang, W Y
AU  - Liang WY
AD  - Department of Geriatrics, Peking University First Hospital, Beijing, China.
FAU - Feng, X R
AU  - Feng XR
AD  - Department of Geriatrics, Peking University First Hospital, Beijing, China.
FAU - Wang, L
AU  - Wang L
AD  - Peking University Center for Human Disease Genomics, Department of Immunology, 
      Health Science Center, Peking University, Beijing, China.
FAU - Fu, Sidney W
AU  - Fu SW
AD  - Department of Medicine, George Washington University Medical Center, Washington 
      DC, USA.
FAU - McCaffrey, Timothy A
AU  - McCaffrey TA
AD  - Department of Medicine, George Washington University Medical Center, Washington 
      DC, USA.
FAU - Liu, M L
AU  - Liu ML
AD  - Department of Geriatrics, Peking University First Hospital, Beijing, China. 
      Electronic address: liumeilin@hotmail.com.
LA  - eng
PT  - Journal Article
DEP - 20170428
PL  - Netherlands
TA  - Gene
JT  - Gene
JID - 7706761
RN  - 0 (Biomarkers)
RN  - 0 (CLU protein, human)
RN  - 0 (CMTM5 protein, human)
RN  - 0 (Chemokines)
RN  - 0 (Clusterin)
RN  - 0 (HLA-DQ alpha-Chains)
RN  - 0 (HLA-DQA1 antigen)
RN  - 0 (MARVEL Domain-Containing Proteins)
RN  - 0 (Osteonectin)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (RNA, Messenger)
RN  - 0 (SPARC protein, human)
RN  - 0 (Tumor Suppressor Proteins)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Biomarkers/blood
MH  - Cell Movement
MH  - Cell Proliferation
MH  - Chemokines/*genetics/metabolism
MH  - Clusterin/genetics/metabolism
MH  - Coronary Artery Disease/blood/drug therapy/*genetics
MH  - Female
MH  - HLA-DQ alpha-Chains/genetics/metabolism
MH  - Human Umbilical Vein Endothelial Cells/drug effects/metabolism/physiology
MH  - Humans
MH  - MARVEL Domain-Containing Proteins/*genetics/metabolism
MH  - Male
MH  - Middle Aged
MH  - Osteonectin/genetics/metabolism
MH  - Platelet Aggregation Inhibitors/pharmacology/*therapeutic use
MH  - RNA, Messenger/*blood
MH  - Tumor Suppressor Proteins/*genetics/metabolism
OTO - NOTNLM
OT  - Biomarkers
OT  - CMTM5
OT  - Cardiovascular agents
OT  - Coronary artery disease
OT  - High on-aspirin platelet reactivity
EDAT- 2017/05/02 06:00
MHDA- 2017/06/20 06:00
CRDT- 2017/05/02 06:00
PHST- 2017/02/02 00:00 [received]
PHST- 2017/04/15 00:00 [revised]
PHST- 2017/04/25 00:00 [accepted]
PHST- 2017/05/02 06:00 [pubmed]
PHST- 2017/06/20 06:00 [medline]
PHST- 2017/05/02 06:00 [entrez]
AID - S0378-1119(17)30303-7 [pii]
AID - 10.1016/j.gene.2017.04.041 [doi]
PST - ppublish
SO  - Gene. 2017 Aug 15;624:56-65. doi: 10.1016/j.gene.2017.04.041. Epub 2017 Apr 28.